Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 mai 2016 18h00 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson’s and Movement Disorders

EMERYVILLE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company’s Phase 3...
10 mai 2016 16h05 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports First Quarter 2016 Financial Results

EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016. Adamas ended the...
06 mai 2016 17h40 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received...
28 avr. 2016 07h00 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients with Parkinson’s Disease

Third Randomized Clinical Trial Meets Primary and Key Secondary Endpoints Conference Call and Webcast Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) EMERYVILLE, Calif., April 28, 2016 ...
27 avr. 2016 20h08 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas to Host Conference Call and Webcast to Provide Company Update

EMERYVILLE, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will...
19 avr. 2016 20h45 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson’s Disease at the American Academy of Neurology Annual Meeting

Anti-dyskinetic Effect Consistent Across Primary and Secondary Outcome Measures EMERYVILLE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced...
14 avr. 2016 16h05 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting

EMERYVILLE, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology,...
23 févr. 2016 16h05 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Fourth Quarter and Full Year 2015 Financial Results

EMERYVILLE, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the fourth quarter and full year ended December 31, 2015....
22 févr. 2016 16h05 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at Two Upcoming Healthcare Conferences

EMERYVILLE, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will...
12 janv. 2016 16h05 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Provides Review of 2015 and Projected Future Milestones

EMERYVILLE, Calif., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today is providing a summary of 2015 corporate highlights and planned future milestones. ...

Page précédente

Page suivante